Free and esterified carnitine in continuous ambulatory peritoneal dialysis patients. Free, acetyl-, medium-and long-chain acylcarnitine and total plasma carnitine concentrations were measured in eight continuous ambulatory peritoneal dialysis (CAPD) patients and eight age-and sex-matched healthy controls. Daily loss of carnitine was also quantified in both groups, by analysis of urine and dialysis fluid. Plasma total carnitine concentration in CAPD patients was not significantly different from controls (42.8 1.6 and 43.1 2.3 irmol/liter, respectively). However, the plasma free carnitine concentration of CAPD patients was significantly lower than that of controls (28.5
concentration in CAPD patients was not significantly different from controls (42.8 1.6 and 43.1 2.3 irmol/liter, respectively). However, the plasma free carnitine concentration of CAPD patients was significantly lower than that of controls (28.5
1.4 and 36.2 2.5 jrmol/liter, respectively; P < 0.05). No difference in the daily loss of total carnitine was found between CAPD patients and controls (269.7
30.0 and 240.5 33.0 jrmol, respectively), but the daily loss of free carnitine was significantly greater in CAPD patients (175.8 17.3 and 105.8
16.4 rmol, respectively; P < 0.05). The ratio of total acylcarnitine (acetyl-, mediumand long-chain acylcarnitine) to free carnitine was significantly greater in plasma of CAPD patients than in controls (P < 0.01) and was lower in daily fluid losses (P < 0.001). These ratio differences suggests that an alteration in acyl group metabolism is occurring in CAPD patients. This may be attributable to an accumulation of medium-and long-chain acylcarnitine in liver of CAPD patients which would be exchanged for plasma free carnitine and/or to a differential loss of free and acylcarnitine across the peritoneal cavity.
Carnitine is a naturally occurring compound which is involved not only in muscular energy metabolism but also in overall cellular metabolism. It is an essential factor in long-chain fatty acid oxidation, facilitating the translocation of fatty acyl groups across the inner mitochondrial membrane [1] . Carnitine may also regulate the cytosolic/mitochondrial acyl-C0A/CoASH ratio, by buffering excess acyl group formation as a result of an impairment in the cellular metabolism [21 or art increase in the rate of cellular energy metabolism [3] , and by doing so may prevent the inhibition of many cellular reactions which depend on existence of a viable pool of CoASH. Carnitine has become of interest in renal failure because it has been shown that patients with end-stage renal failure on hemodialysis have subnormal plasma and muscle free carnitine and/or elevated acylcarnitine concentrations [4-81, although the decline in muscle carnitine concentration has not been Received for publication May 22, 1995 and in revised form August 23, 1995 Accepted for publication August 24, 1995 © 1996 by the International Society of Nephrology consistently confirmed [9, 10] . It is possible that these deficiencies attributed to the loss of carnitine during hemodialysis could contribute to the muscular fatiguability and weakness that renal failure patients experience. Whether a similar situation exists in patients undergoing continuous ambulatory peritoneal dialysis (CAPD) is unclear. Previous studies have shown plasma carnitine of CAPD patients to be comparable [6, 7, [11] [12] [13] , towards being lower [8] or significantly lower [14] compared with controls.
However, the controls in these previous studies were not age-and sex-matched, which would have been desirable since plasma carnitine is influenced by these two factors [15, 16] , and may therefore explain these equivocal findings.
The aims of the present study therefore were to assess the plasma carnitine status of CAPD patients and to quantify the daily loss of carnitine in this patient group compared with age-and sex-matched healthy control subjects.
Methods
Eight patients (mean age 43.6 4.8 years; range 20 to 60 years; Table 1 ) undergoing CAPD treatment (mean duration 27 months 14; range 4 to 120 months) were recruited from those attending the CAPD out-patient clinic and matched with age-and sexhealthy controls. The mean age of controls was 43.3 4.7 years (range 20 to 59 years; Table 1 ). A 10 ml sample of venous blood was obtained at least seven hours post-prandially from an antecubital vein and was mixed with lithium heparin. Following centrifugation (10 mm at 3,000 rpm), the plasma was snap frozen in liquid nitrogen and stored at -80°C. Both controls and CAPD patients undertook a 24-hour urine collection using a 2 liter container containing 5 ml of a 0.67 mol/liter thymol solution in isopropanol. CAPD patients also collected their dialysate fluids over the same period as their 24 -hour urine sample. Following collection, the contents of each dialysis bag and urine collection were pooled, mixed thoroughly and 2 aliquots (10 ml) of each fluid were removed, snap frozen in liquid nitrogen and stored at -80°C.
Sample aliquots of plasma, urine and peritoneal dialysis fluid were extracted with chloroform/methanol (3/2, vol/vol). After evaporation, the residue was dissolved in 0.1 mol/liter KOH, incubated at 50°C for two hours and, subsequent to neutralization with 0.5 mol/liter HC1, used for determination of total carnitine using an enzymatic assay containing radioisotopic substrate, as described previously [17] . Free carnitine was determined by were measured in 0.5 mol/liter perchioric acid deproteinized plasma, urine and peritoneal dialysis fluid using an enzymatic assay containing radioisotopic substrate, as described previously [18] . All measurements were performed in duplicate. Total acylcarnitine concentrations were obtained by subtracting free carnitine from total carnitine concentrations. Medium-and long-chain acylcarnitine concentrations were obtained by subtracting free carnitine and acetylcarnitine from total carnitine concentrations. The daily loss of free, acetyl, medium-and long-chain acylcarnitine and total carnitine in each CAPD patient was calculated by summing the loss in dialysate and urine. For each control, the 
Results
The plasma total carnitine concentration of CAPD patients was no different from that of controls (42.8
1.6 and 43.1 2.3 xmol/liter, respectively; P > 0.05; Fig. 1 ). However, plasma free carnitine concentration of CAPD patients was significantly lower than that of controls (28.5
1.4 and 36.2 2.5 mo1/liter, respectively; P < 0.05; Fig. I ). Though plasma acetylcarnitine concentrations did not differ between the two groups ( Fig. 1) , this ester represented only 40% of the total plasma esterified carnitine in CAPD patients, but 70% of that in the controls. Comparison of plasma medium-and long-chain acylcarnitine concentration revealed a significantly greater concentration in CAPD patients compared with controls (8.56 1.93 and 2.39 0.93 1xmol/liter, respectively; P = 0.01; Fig. 1 ), the excess being of a similar magnitude to the deficit in plasma free carnitine. The total plasma acyl (acetyl-, medium-and long-chain acylcarnitine) to free carnitine ratio was significantly greater in CAPD patients compared with controls (0.52 0.08 and 0.20 0.05, respectively; P < 0.01). This was attributable to the lower plasma free carnitine concentration and greater plasma medium-and long-chain carnitine concentration in CAPD patients. Figure 2 A and B show the renal and peritoneal clearances, respectively, calculated in CAPD patients. Calculations of cumulative (renal + peritoneal) clearances showed comparable total carnitine clearance between the two groups (Fig. 2C) . However, Fig. 3C ). The ratio of total acylcarnitine to free carnitine in daily combined fluid losses (urine plus peritoneal dialysis fluid) were significantly lower in CAPD patients compared with controls (0.50 0.05 and 1.36 0.14, respectively; P < 0.001).
Discussion
The major findings of present study were, firstly, that patients who had undergone CAPD treatment for a mean duration of 27 months have a significantly lower plasma free carnitine concentration compared to a control group matched by age and sex. Most previous studies have shown comparable plasma free carnitine concentrations in CAPD patients [6, 7, [11] [12] [13] . Only one previous study has shown a significantly lower plasma free carnitine concentrations in CAPD patients [141. Secondly, the measurement of daily carnitine loss via analysis of urine and dialysis fluids showed a significantly greater loss of free carnitine and acetylcarnitine in CAPD patients compared with controls. These latter findings were apparent despite the fact that the daily losses of total carnitine of both groups were similar, therefore indicating that a redistribution of carnitine from its free form to an esterified form occurred in the CAPD patients. Thirdly, this redistribution of carnitine in CAPD patients, which has previously been reported [7] , was reflected solely by an increase in plasma mediumand long-chain acylcarnitine concentrations. Carnitine is present in both plasma and urine in free and esterified forms. Plasma free carnitine concentration which is ageand sex-related [15, 16] normally represents 80% of the total carnitine concentration (Fig. 1) . The remaining 20% comprise the csterified fraction, of which about -70% exists in the acetylated form (Fig. 1) . However, a redistribution of plasma free carnitine to the esterified form has been reported to occur in disease [19, 201, fasting [21] , and during exercise [22] . This is thought to result from carnitine's ability to buffer increases in tissue acyl group levels [2] . In agreement with this latter function, the present study showed that a similar redistribution of plasma free carnitine into an esterified form occurred in the plasma of CAPD patients. This contributed to a significantly lower free to total carnitine ratio in the plasma of CAPD patients compared with controls (0.67 0.03 and 0.84 0.03, respectively; P C 0.01) and to a significantly greater total acyl to free carnitine ratio (0.52 0.08 and 0.20 0.05, respectively; P C 0.01). These abnormal ratios have been cited as a possible cause of a "relative carnitine deficiency" [23, 24] . However, the novel finding of the present study was that this redistribution of plasma free carnitine into an esterified form in the CAPD patients was reflected solely by an increase in plasma medium-and long-chain acylcarnitine concentrations (Fig. 1) . It is worth mentioning that this change is in contrast to what it is seen in conditions of human ketosis resulted from decreased insulin secretion, where the redistribution is reflected mainly by an increase in short-chain acylcarnitines [20, 21] . Since acetylcarnitine was the major plasma carnitine ester in the control subjects, this change in the profile of plasma carnitine esters in CAPD patients may reflect an impairment of acyl group oxidation occurring in this patient population. Indeed, the intravenous supplementation of plasma with carnitine in hemodialysis patients has been shown to increase markedly not only plasma free carnitine but also total acylcarnitine concentrations, resulting in their ratio continuing to be abnormal [7] . This suggests that there is an excess of acyl groups which are buffered by the administered carnitine. Possible sites for this type of occurrence could be liver where it is thought that an elevation of acyl groups, arising primarily from an impairment of their oxidation, would be buffered by carnitine. It has been suggested that plasma and liver can exchange free carnitine for esterified forms during cellular metabolic stress [22] . There is no evidence to suggest, at least for healthy subjects, that an exchange of esterified carnitine for the free carnitine occurs between skeletal muscle and plasma, as it has been shown that during metabolic stress (muscle contraction) the decline in muscle free carnitine was well matched by similar increases in muscle carnitine esters, mainly acetylcarnitine [3, 22] . Therefore, an alternative explanation for the present findings could be that there was a slower and/or less efficient clearance of medium-and long-chain aeylcarnitine by nephrons and/or across the peritoneal cavity in the CAPD patients. It is not completely clear what effect a slower rate of medium-and long-chain acylcarnitine excretion would have upon the metabolism of CAPD patients. Since acylcarnitines and aeyl-CoAs are in equilibrium via earnitine acyltransferases [25] an accumulation of the former could serve as a reservoir of acyl groups for acyl-CoA formation. Acyl-CoA compounds, especially long-chain acyl groups, have deleterious effects on cellular membrane integrity due to their detergent properties [26] and have been shown to have an inhibitory effect on adenine nucleotide translocation [27] . These effects may account for some of the pathophysiology of chronic renal failure, including atherosclerotic cardiovascular disorders.
A second aim of the present study was to quantify the daily losses of free and esterified earnitine in CAPD patients. The daily loss of total earnitine measured via analysis of urine and dialysis fluids was not different in CAPD patients when compared with controls (Fig. 3C) . However, the daily loss of free carnitine in CAPD patients was 1.7-fold greater than that of controls (P C 0.05). The principal route for this increased loss was via peritoneal dialysis fluid, since the magnitude of loss was fivefold greater than that via urine excretion (Fig. 3 A, B) . CAPD patients also experienced a significantly greater daily loss of acetylcarnitine (Fig. 3C) .
However, the increased elimination of free carnitine and acetylearnitine was matched by a similar decrease in the extent of medium-and long-chain acylearnitine loss. The ratio of total aeylearnitine to free carnitine in daily fluid losses (urine + peritoneal dialysis fluid) were significantly lower in CAPD patients compared with controls (0.50 0.05 and 1.36 0.14, respectively; P C 0.001). These findings could possibly be explained by differences in clearance rates. In controls, the total acylcarnitine renal clearance was eightfold greater than that of free earnitine (16.87 3.88 and 2.15 0.41 mI/mm, respectively), which was probably attributable to the preferential renal tubular reabsorbtion of free carnitine. In CAPD patients, however, the cumulative peritoneal and renal clearance of acylearnitine was similar to that of free earnitine (4.87 0.78 and 4.43 0.63 mI/mm, respectively; Fig. 2C ). These data also showed that the free earnitine peritoneal clearance (3.77 0.70) was actually greater then the free earnitine renal clearance in controls (2.15 0.41). This may be attributable to a differential loss of the free form across the peritoneal cavity resulting from the more rapid diffusion of small molecules like free and acetylearnitine. It has previously been shown that endogenous medium size molecules (350 to 2,000 Daltons) are more efficiently transferred during CAPD than during other forms of dialysis treatment [28] . Although the daily acetylearnitine losses by CAPD patients were significantly greater than by controls (Fig. 3C) , the respective plasma levels differed only slightly ( Fig. 1) and it seems unlikely that the greater daily losses were directly harmful. However, because of the potential deleterious effects of long-chain acylCoA accumulation discussed previously, it may be of more metabolic significance that the plasma level of medium-and long-chain aeylearnitine of CAPD patients was three times greater than that of controls (Fig. 1 ).
In conclusion, the present results demonstrate that the plasma total earnitine concentration and the daily loss of total carnitine were similar when comparing CAPD patients with age-and sex-matched controls. However, the plasma concentration of free carnitine was lower in CAPD patients than in controls and, conversely, the daily loss of free earnitine was greater. The ratio of total aeylearnitine to free earnitine was significantly greater in plasma of CAPD patients than in controls and lower in daily fluid losses. These ratio differences may have resulted from an exchange of plasma free earnitine with hepatic medium-and longchain acylcarnitines and/or to a differential loss of free earnitine and aeylearnitine across the peritoneal cavity. Finally, given the likely rise in the concentration of plasma medium-and long-chain aeylearnitines as a result of earnitine therapy [7] , our observations suggest a need for some caution in the use of earnitine supplementation in CAPD patients, until more is known of the metabolic consequences relating to the accumulation of these compounds.
